Overview

TBI Dose De-escalation for Fanconi Anemia

Status:
Completed
Trial end date:
2020-10-09
Target enrollment:
Participant gender:
Summary
This is a single arm, total body irradiation (TBI) trial. All patients will be prescribed TBI 300 cGy with the goal of evaluating secondary endpoints.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Cyclophosphamide
Everolimus
Fludarabine
Fludarabine phosphate
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus